New York, NY -- (SBWIRE) -- 01/08/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Aeropostale Inc (NYSE:ARO), CEL-SCI Corporation (NYSEMKT:CVM), Achillion Pharmaceuticals, Inc (NASDAQ:ACHN), Monster Worldwide, Inc (NYSE:MWW)
Aeropostale Inc (NYSE:ARO) showed a volume of 2.08 million shares by the end of last trade whereas the average volume of the stock remained 3.02 million shares. The stock opened the session at $9.08 but then moved to $8.87. At that price, the stock showed a negative performance of -1.33%. Aeropostale, Inc., (Aeropostale) is a mall-based, specialty retailer of casual apparel and accessories, principally targeting 14 to 17 year-old young women and men through its Aeropostale stores and 4 to 12 year-old kids through its P.S. from Aeropostale stores. P.S. from Aeropostale products can be purchased in P.S. from Aeropostale stores, in certain Aeropostale stores, and online at www.ps4u.com. As of January 28, 2012, it operated 986 Aeropostale stores, consisting of 918 stores in 50 states and Puerto Rico, 68 stores in Canada,
Will ARO Get Buyers Even After The Recent Rally? Find Out Here
CEL-SCI Corporation (NYSEMKT:CVM) opened the session at $0.70 and closed the session at $0.730. The stock showed a positive performance of 5.78% in previous trading session. Traded with volume of 2.07 million shares in the prior session and the average volume of the stock remained 696,417.00 shares. CEL-SCI Corporation (CEL-SCI) is engaged in the business of Multikine cancer therapy; New cold fill manufacturing service to the pharmaceutical industry, and ligand epitope antigen presentation System (LEAPS) technology, with two products, hemagglutinin type 1 and neuraminidase type 1 (H1N1) swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine.
For How Long CVM will fight for Profitability? Read This Trend Analysis report
Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) opened the session at $3.39 and closed the session at $3.31. The stock showed a negative performance of -2.07% in previous trading session. Traded with volume of 2.05 million shares in the prior session and the average volume of the stock remained 2.15 million shares. The beta of the stock remained 0.37. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV,
Why Should Investors Buy ACHN After the Recent Fall? Just Go Here and Find Out
Monster Worldwide, Inc (NYSE:MWW) the stock advanced 0.43% and finished the session at $6.98. Traded with volume of 1.96 million shares in the prior session and the average volume of the stock remained 2.51 million shares. The beta of the stock remained 2.78. Monster Worldwide, Inc. (Monster Worldwide) is parent company of Monster, the global online employment solution. With a presence in approximately 55 countries globally, including key markets in North America, Europe, South America and the Asia-Pacific region, Monster offers online recruiting solutions. Through online media sites and services, Monster Worldwide delivers audiences to advertisers. It operates in three segments: Careers-North America, Careers-International, and Internet Advertising & Fees.
Will MWW Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)